Nelson Bennett, MD
Urology · Chicago, ILNPI 1366529240
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (36.2%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. Endo Pharmaceuticals Inc. accounts for 68.1% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2019 at $19,874 and has fallen 99.3% since, to $143 in 2025. Among urology clinicians in IL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 67 payments — averaging $552.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Endo Pharmaceuticals Inc.$25K
- Coloplast$11K
- Cook Incorporated$700
- Boston Scientific$214
- Antares Pharma, Inc.$50
- Endo USA, Inc.$32
- plus $26 from 2 others
Across 4 payments — averaging $1227.25 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Endo USA, Inc.$5K
What the payments were for
- Consulting fees$13,40536%
- Speaking & faculty fees$10,35028%
- Travel & lodging$7,32620%
- Food & beverage$2,7017%
- Education$3,2649%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Endo Pharmaceuticals Inc. | 34 | $25,246 |
| Coloplast | 25 | $10,778 |
| Cook Incorporated | 1 | $700 |
| Boston Scientific | 3 | $214 |
| Antares Pharma, Inc. | 1 | $50 |
| Endo USA, Inc. | 1 | $32 |
| Hollister Incorporated | 1 | $14 |
| Metuchen Pharmaceuticals | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$37,046 in reported general payments places this provider in the 90th percentile of 550 urology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Testosterone | 95 | $19,865 |
| MyrbetriqMirabegron | 16 | $10,924 |
| Cabergoline | 60 | $10,355 |
| Testosterone Cypionate | 64 | $3,076 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 109 | $2,216 |
| Tamsulosin Hcl | 49 | $982 |
| Finasteride | 43 | $600 |
| Pentoxifylline | 20 | $242 |
| Anastrozole | 19 | $87 |
Paid to pharmacies, not to this prescriber.
Other urology in Chicago
- Gary SteinbergChicago$529K
- Simone CrivellaroChicago$526K
- Brian HelfandChicago$517K
- Ashley RossChicago$404K
- Amy KrambeckChicago$356K
- Kevin ZornChicago$274K
- Joshua MeeksChicago$248K
- Edward SchaefferChicago$209K
- Paul YonoverChicago$179K
- Omer RaheemChicago$148K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.